SPRB I sold a ton afterhours, I think it went too far but who knows. Oppenheimer did give it a $15 price target which is what sent it higher. As for crashing .. sure, I mean it went up 150%. And its a an early stage dinky cap biotech company.... all of those have no way of making money so sure, it raised all its cash throught issuance of debt and equities, the all do. Thats not new, anyone investing in dinky cap or even larger cap early stage biotechs invests in companies that don't make money.
But, for me as investor ... I don't buy many biotechs... too much research involved. But, broken biotechs.. those that have sold off but have so much cash already...almost twice the market cap when it sold off to its low the other day.... which is about two years of operations; and they have actual stuff in their pipeline which is of value (see Oppenheimer), those are worth the trade.
I'd buy a crash into the mid two's again in a heartbeat. Would you buy if it went back near its lows?
Market Data 
Markets 
AI
